Ascendis Pharma A/S’s (ASND) “Outperform” Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a report issued on Friday, Marketbeat.com reports. The firm currently has a $181.00 price objective on the biotechnology company’s stock.

Several other research firms have also recently weighed in on ASND. Jefferies Financial Group lifted their target price on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th. TD Cowen boosted their price objective on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Evercore ISI increased their target price on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 17th. Citigroup boosted their price target on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Finally, Bank of America upped their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $191.77.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $126.51 on Friday. The firm’s 50 day moving average price is $132.30 and its two-hundred day moving average price is $132.60. Ascendis Pharma A/S has a twelve month low of $90.13 and a twelve month high of $161.00. The stock has a market cap of $7.67 billion, a price-to-earnings ratio of -15.66 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. On average, research analysts forecast that Ascendis Pharma A/S will post -7.3 EPS for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Several large investors have recently made changes to their positions in ASND. SG Americas Securities LLC bought a new position in shares of Ascendis Pharma A/S in the 1st quarter valued at approximately $288,000. ProShare Advisors LLC grew its holdings in Ascendis Pharma A/S by 9.9% during the first quarter. ProShare Advisors LLC now owns 4,025 shares of the biotechnology company’s stock valued at $608,000 after purchasing an additional 361 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Ascendis Pharma A/S by 1,461.1% in the first quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock valued at $37,849,000 after purchasing an additional 234,446 shares during the period. Bessemer Group Inc. lifted its stake in shares of Ascendis Pharma A/S by 61.0% in the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after buying an additional 332 shares during the last quarter. Finally, Nan Fung Group Holdings Ltd bought a new stake in shares of Ascendis Pharma A/S during the 1st quarter worth $2,056,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.